CEA CAR-T therapy after surgery for colorectal cancer spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a special immune cell therapy (CAR-T) that targets a protein called CEA on cancer cells. It is for people with colorectal cancer that has spread to the lining of the belly (peritoneum) and who have already had surgery to remove as much of the spread as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to the lining of your belly (peritoneal metastases).
- You have already tried standard treatments (like chemotherapy) and they stopped working or you could not tolerate them.
- You have had surgery to remove the cancer from your belly lining, and the surgery was successful enough (score CC-0 to CC-2).
- Your cancer cells make a protein called CEA (tested on the tissue removed during surgery).
- You are generally in good health, with no major organ problems, and can care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
Hear when a new Peritoneal Metastases From Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.